Education
About Us
Working with TipRanks
Follow Us
Shanghai Pharmaceuticals Holding Co Ltd Class H (HK:2607)
:2607
2607 Stock Chart & Stats
HK$11.91
-HK$0.08(-0.65%)
At close: 4:00 PM EST
HK$11.91
-HK$0.08(-0.65%)
Day’s Range― - ―
52-Week RangeHK$10.06 - HK$13.12
Previous CloseN/A
Volume2.05M
Average Volume (3M)2.90M
Market Cap
HK$65.00B
Enterprise ValueHK$88.22B
Total Cash (Recent Filing)HK$44.55B
Total Debt (Recent Filing)HK$61.60B
Price to Earnings (P/E)7.2
Beta0.69
Next Earnings
Mar 31, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend Yield2.67%
Share Statistics
EPS (TTM)0.21
Shares Outstanding919,072,700
10 Day Avg. Volume2,690,085
30 Day Avg. Volume2,904,360
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)0.61
Price to Sales (P/S)0.16
P/FCF Ratio12.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Position & Distribution NetworkA nationwide distribution footprint and deep hospital/pharmacy relationships create durable revenue access and scale advantages. Over 2–6 months this supports stable order flow, negotiating leverage with suppliers, and resilience versus regional competitors when rolling out new products or partnerships.
Diversified Business SegmentsMultiple business lines (manufacturing, distribution, hospitals, retail pharmacies) lower single-segment risk and enable cross-selling of medicines and services. This structural diversification supports steadier revenues and allows reallocation of capital to higher-return segments over time.
Consistent Revenue GrowthSustained top-line growth indicates continued market demand and successful commercial execution. Over the medium term, steady revenue expansion provides a base for margin recovery initiatives and R&D investment, improving long-term competitiveness despite current margin pressure.
Bears Say
Weak Cash ConversionPersistent low operating cash conversion signals working-capital intensity and earnings that don’t convert to liquid funds. This structurally limits the company’s ability to self-fund capex, M&A or dividends and raises reliance on external financing over a multi-quarter horizon.
Rising LeverageAn upward leverage trend reduces financial flexibility and increases sensitivity to interest-rate or funding shocks. For a working-capital intensive distributor, higher debt magnifies cash-flow stress during seasonal swings or slower collections, constraining long-term strategic options.
Structurally Thin MarginsLow and compressing margins reflect the distribution-heavy model and pricing pressure. Persistently thin profitability limits internal reinvestment, heightens reliance on volume growth for earnings improvement, and makes returns vulnerable to cost inflation or competitive discounting.
Shanghai Pharmaceuticals Holding Co News
2607 FAQ
What was Shanghai Pharmaceuticals Holding Co Ltd Class H’s price range in the past 12 months?
Shanghai Pharmaceuticals Holding Co Ltd Class H lowest stock price was HK$10.06 and its highest was HK$13.12 in the past 12 months.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap is HK$65.00B.
When is Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date is Mar 31, 2026 which is in 36 days.
How were Shanghai Pharmaceuticals Holding Co Ltd Class H’s earnings last quarter?
Shanghai Pharmaceuticals Holding Co Ltd Class H released its earnings results on Oct 30, 2025. The company reported HK$0.215 earnings per share for the quarter, missing the consensus estimate of HK$0.317 by -HK$0.102.
Is Shanghai Pharmaceuticals Holding Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Pharmaceuticals Holding Co Ltd Class H’s price is currently Overvalued.
Does Shanghai Pharmaceuticals Holding Co Ltd Class H pay dividends?
Shanghai Pharmaceuticals Holding Co Ltd Class H pays a Notavailable dividend of HK$0.317 which represents an annual dividend yield of 2.67%. See more information on Shanghai Pharmaceuticals Holding Co Ltd Class H dividends here
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate is 0.18.
How many shares outstanding does Shanghai Pharmaceuticals Holding Co Ltd Class H have?
Shanghai Pharmaceuticals Holding Co Ltd Class H has 919,072,700 shares outstanding.
What happened to Shanghai Pharmaceuticals Holding Co Ltd Class H’s price movement after its last earnings report?
Shanghai Pharmaceuticals Holding Co Ltd Class H reported an EPS of HK$0.215 in its last earnings report, missing expectations of HK$0.317. Following the earnings report the stock price went up 0.735%.
Which hedge fund is a major shareholder of Shanghai Pharmaceuticals Holding Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2607
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pharmaceuticals Holding Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.71%
12-Months-Change
Fundamentals
Return on Equity
7.53%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Shanghai Pharmaceuticals Holding Co Ltd Class H
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Technical Analysis
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---